Catalyst Wire Dossier Catalyst Wire Dossier

Pemvidutide

Pemvidutide · Altimmune, Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Pemvidutide, covering 2025-11-19 to 2026-03-20. Get the full timeline:

Most recent: Clinical Trial Update: RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) [Phase 2]

See pricing